Crohn's Disease

Survey results supported prior research that found one-quarter to one-third of patients with inflammatory bowel diseases report posttraumatic stress symptoms linked to their disease experience.

Mirikizumab demonstrated sustained safety and efficacy at 52-weeks in patients with Crohn’s disease; these data support the ongoing VIVID phase 3 study, Bruce Sands, MD, Icahn School of Medicine told Healio Gastroenterology.

Entyvio and Stelara were commonly used in combination therapy for the treatment of inflammatory bowel disease, according to research at Digestive Disease Week.

Stelara and Humira demonstrated rapid onset of action and effectiveness in the treatment of patients with moderate to severe Crohn’s disease, Bruce Sands, MD, Icahn School of Medicine, told Healio Gastroenterology.

Researchers identified novel candidate biomarkers for infliximab response after unsupervised plasma proteomic analysis in pediatric patients with Crohn’s disease, according to a presentation at Digestive Disease Week.

There was a 15-fold increase of venous thromboembolism among the pediatric inflammatory bowel disease population compared with the general population, according to presenter at Digestive Disease Week.

In this video exclusive, Florian Rieder, MD, and Jiannan Li, MD, PhD, from Cleveland Clinic, discussed a study that looked at Cadherin-11 levels in patients with inflammatory bowel disease, in particular Crohn’s disease.

Remo Panaccione, MD, University of Calgary, tells Healio Gastroenterology that Skyrizi induced clinical remission and endoscopic response in patients with Crohn’s disease, according to results from the ADVANCE and MOTIVATE trials.

The AGA published guidelines in Gastroenterology for the management of moderate-to-severe luminal and fistulizing Crohn’s disease.

In an exclusive video with Healio Gastroenterology, Loren Laine, MD, FACG, chair of the Digestive Disease Week counsel, Yale School of Medicine, highlighted a few presentations from Digestive Disease Week.